BRAF

Universal Cellular Machinery · Phosphorylation & Kinase Signaling Cascades

Why must a BRAF result specify the exact alteration?

BRAF encodes a kinase in the RAS/MAPK growth-signaling pathway. Different alterations and testing contexts can have different developmental or tumor-related meanings, so the gene name is insufficient for treatment selection.

Common Gene Name
B-Raf proto-oncogene, serine/threonine kinase
NCBI Gene ID
673
Chromosome
7

Clinical Evidence Status

Actionability report availableEstablished disease relationshipTumor or drug-label biomarker context

These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.

Answer Sources

Explore supporting evidence (26 records)
Condition or drugEvidenceGrade / statusContextSource
Noonan syndromeClinGen gene-disease validityModerateAutosomal dominantView source
2018-07-24
Noonan syndrome with multiple lentiginesClinGen gene-disease validityLimitedAutosomal dominantView source
2018-07-24
cardiofaciocutaneous syndromeClinGen gene-disease validityDefinitiveAutosomal dominantView source
2018-07-24
Costello syndromeClinGen gene-disease validityDisputedAutosomal dominantView source
2018-07-24
Langerhans cell histiocytosisMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
Gastrointestinal stromal tumorMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
Giant congenital melanocytic nevusMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
Erdheim-Chester diseaseMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
Lung cancerMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
Multiple myelomaMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
CholangiocarcinomaMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
MelanomaMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2018-07
Noonan syndromeClinGen clinical actionabilityScored report; not a validity gradeAdultView source
2020-04-22
Noonan syndromeClinGen clinical actionabilityScored report; not a validity gradePediatricView source
2022-02-09
Atezolizumab (5)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Binimetinib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Cetuximab (3)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
CobimetinibFDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Dabrafenib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Encorafenib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Nivolumab (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Nivolumab and Relatlimab-rmbw (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Pembrolizumab (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
TovorafenibFDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Trametinib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Vemurafenib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source

Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.

← Back to Universal Cellular Machinery